This invention relates to a method for repair and reconstitution of invertebral discs in a subject which involves administration of STRO-1′ multipotent cells. The method of the invention is useful in the treatment of spinal conditions characterized by degeneration of the invertebral disc.

Pharmaceutical compositions, more specifically poloxamer copolymer-based compositions and hyaluronic acid-based compositions, containing amelogenin, are useful for promoting periodontal or orthopedic soft or hard tissue regeneration, wound closure, and skin regeneration and rejuvenation. The composition can contain a non-biodegradable thermosensitive pharmaceutically acceptable poloxamer copolymer in an amount of 18% to 30% by weight; amelogenin in an amount of 0.005% to 3% by weight; a disaccharide in an amount of 0.05% to 5% by weight; and an amino acid selected from alanine, glycine, isoleucine, leucine, proline, valine, and a mixture thereof in an amount of 0.05% to 5% by weight.

Pharmaceutical compositions, more specifically poloxamer copolymer-based compositions and hyaluronic acid-based compositions, containing amelogenin, are useful for promoting periodontal or orthopedic soft or hard tissue regeneration, wound closure, and skin regeneration and rejuvenation. The composition can contain a non-biodegradable thermosensitive pharmaceutically acceptable poloxamer copolymer in an amount of 18% to 30% by weight; amelogenin in an amount of 0.005% to 3% by weight; a disaccharide in an amount of 0.05% to 5% by weight; and an amino acid selected from alanine, glycine, isoleucine, leucine, proline, valine, and a mixture thereof in an amount of 0.05% to 5% by weight.

The present invention provides compounds and compositions thereof which are useful as inhibitors of Bruton's tyrosine kinase and which exhibit desirable characteristics for the same.

The present invention discloses a fused polypeptide with multifunctional activity and use thereof, relating to the field of biopharmaceuticals. In the fused polypeptide with multifunctional activity, the polypeptide contains the following domains: N-Acetyl-Ser-Asp-Lys-Pro, Ser-Asp-Lys-Pro, Thr-Ser-Leu-Asp-Ala-Ser-Ile-Ile-Trp-Ala-Met-Met-Gln-Asn, and Leu-Ser-Lys-Leu, or domains in which any amino acid in the foregoing domains is mutated. The fused polypeptide can treat various fibrotic diseases including pulmonary fibrosis, hepatic fibrosis, skin fibrosis, renal fibrosis, and myocardial fibrosis, and has activity of inhibiting a plurality of types of human tumor cells.

The present invention discloses a fused polypeptide with multifunctional activity and use thereof, relating to the field of biopharmaceuticals. In the fused polypeptide with multifunctional activity, the polypeptide contains the following domains: N-Acetyl-Ser-Asp-Lys-Pro, Ser-Asp-Lys-Pro, Thr-Ser-Leu-Asp-Ala-Ser-Ile-Ile-Trp-Ala-Met-Met-Gln-Asn, and Leu-Ser-Lys-Leu, or domains in which any amino acid in the foregoing domains is mutated. The fused polypeptide can treat various fibrotic diseases including pulmonary fibrosis, hepatic fibrosis, skin fibrosis, renal fibrosis, and myocardial fibrosis, and has activity of inhibiting a plurality of types of human tumor cells.

The present disclosure is directed to a composition or nutritional product containing a cannabinoid in combination with an adjuvant, such as a Type II collagen. The different nutraceutical agents are capable of synergistically working together to improve the health and well-being of a human or animal. For instance, the nutritional product can be used in many different applications, such as to treat joint discomfort and pain, and/or to improve muscular health.

Described is a method for treating an infectious disease, cancer, or myeloproliferative disease in a subject, wherein a 50 to 540 μg dose of a pegylated type I interferon is administered to the subject at a regular interval for a treatment period, the interval being 3 to 8 weeks.

The present invention provides antibodies, or antigen-binding fragment thereof, which specifically bind to tumor necrosis factor (TNF)-like ligand 1A(TL1A) The invention further provides a method of obtaining such antibodies and nucleic acids encoding the same. The invention further relates to compositions and therapeutic methods for use of these antibodies for the treatment and/or prevention of TL1A mediated diseases, disorders or conditions.

The application provides biocompatible carriers comprising bone forming and/or cartilage forming cells and methods for making them. The application further provides pharmaceutical compositions comprising said ATMPs and method of treatments using said ATMPs. The application further relates to said ATMPS for use in the treatment of bone disorders, cartilage disorders and joint disorders. The current invention further relates to method of treatments of bone disorders, cartilage disorders and joint disorders.